# A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs)

> **NCT05905458** · PHASE2 · COMPLETED · sponsor: **Chengdu Suncadia Medicine Co., Ltd.** · enrollment: 54 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** HRS9950 tablets
- **DRUG:** HRS9950 tablets
- **DRUG:** HRS9950 placebo tablets

## Key facts

- **NCT ID:** NCT05905458
- **Lead sponsor:** Chengdu Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-28
- **Primary completion:** 2024-11-22
- **Final completion:** 2024-11-22
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05905458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05905458, "A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05905458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*